Herein, we demonstrate that a combination of RRAD inhibition with chemotherapeutic agents in RRAD-expressed cell lines of GC or CRC resulted in more effective antitumor efficacy than monotherapy. The gene discussed is RRAD; the disease is gastric cancer.